Safety and efficacy of argatroban on elderly patients with acute cerebral infarction over 6 hours after onset

Objective To study the safety and efficacy of argatroban on elderly patients with acute cerebral infarction over 6 hours after onset. Methods Ninety-eight patients with acute cerebral infarction over 6 hours from August 2016 to October 2017 in Linfen People’s Hospital were selected and were divided into control group and treatment group by randomization list, with 49 cases in each group. Patients in control group were treated by clinical routine treatment. Patients in treatment group were treated with argatroban on the basis of treatment for control group. The National Institute of Health stroke scale (NIHSS) score, activity of daily living (ADL) score, adverse reactions and therapeutic effect before treatment and after 14 days of treatment were compared between the two groups. Results The total effective rate of control group (77.55%) was lower than that of treatment group (91.83%), the difference was statistically significant (P<0.05). The NIHSS score of control group (6.27±3.12) was significantly higher than that of treatment group (3.87±2.62) after 14 days of treatment, and the difference was statistically significant (P<0.05). The ADL score of control group (40.17±7.75) was significantly higher than that of treatment group (36.25±8.48) after 14 days of treatment, and the difference was statistically significant (P<0.05). The blood routine and coagulation status in treatment group were in a reasonable range, and no bleeding or gastrointestinal tract adverse reaction was found. Conclusions Argatroban in the treatment of elderly patients with acute cerebral infarction with over 6 hours after onset is safe and effective. It can improve the clinical efficacy, NIHSS score and ADL score, with fewer adverse reactions. Key words: Acute senile cerebral infarction over 6 hours after onset; Acagtran; Effectiveness